OMBITASVIR/ABT-450/RITONAVIR õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

ombitasvir/abt-450/ritonavir õhukese polümeerikattega tablett

abbvie deutschland gmbh & co. kg - ombitasviir+paritapreviir+ritonaviir - õhukese polümeerikattega tablett - 12,5mg+75mg+50mg 64tk

DASABUVIR õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

dasabuvir õhukese polümeerikattega tablett

abbvie deutschland gmbh & co. kg - dasabuviir - õhukese polümeerikattega tablett - 250mg 64tk

TRANSMETIL tablett Eesti - eesti - Ravimiamet

transmetil tablett

abbvie s.r.l. - ademetioniin - tablett - 500mg 10tk

Rinvoq Euroopa Liit - eesti - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

ALUVIA õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

aluvia õhukese polümeerikattega tablett

abbvie deutschland gmbh & co. kg - lopinaviir+ritonaviir - õhukese polümeerikattega tablett - 200mg+50mg 120tk

DALSY suukaudne suspensioon Eesti - eesti - Ravimiamet

dalsy suukaudne suspensioon

abbvie s.r.l. - ibuprofeen - suukaudne suspensioon - 20mg 1ml 150ml 1tk

EPCORITAMAB süstelahuse kontsentraat Eesti - eesti - Ravimiamet

epcoritamab süstelahuse kontsentraat

abbvie deutschland gmbh & co. kg - epkoritamab - süstelahuse kontsentraat - 48mg 0.8ml 0.8ml 1tk

EPCORITAMAB süstelahuse kontsentraat Eesti - eesti - Ravimiamet

epcoritamab süstelahuse kontsentraat

abbvie deutschland gmbh & co. kg - epkoritamab - süstelahuse kontsentraat - 4mg 0.8ml 0.8ml 1tk

BICLAR suukaudse suspensiooni graanulid Eesti - eesti - Ravimiamet

biclar suukaudse suspensiooni graanulid

abbvie s.r.l. - klaritromütsiin - suukaudse suspensiooni graanulid - 125mg 5ml 120ml 1tk

KLACID 125MG/5ML suukaudse suspensiooni graanulid Eesti - eesti - Ravimiamet

klacid 125mg/5ml suukaudse suspensiooni graanulid

abbvie s.r.l. - klaritromütsiin - suukaudse suspensiooni graanulid - 25mg 1ml 60ml 1tk; 25mg 1ml 100ml 1tk